Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer. Survival analysis was conducted to determine if the prevalence of preoperative blood monocytes correlates with survival in patients with pancre...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2013-07, Vol.19 (13), p.3404-3415 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3415 |
|---|---|
| container_issue | 13 |
| container_start_page | 3404 |
| container_title | Clinical cancer research |
| container_volume | 19 |
| creator | SANFORD, Dominic E BELT, Brian A WANG-GILLAM, Andrea EBERLEIN, Timothy J DENARDO, David G GOEDEGEBUURE, Simon Peter LINEHAN, David C PANNI, Roheena Z MAYER, Allese DESHPANDE, Anjali D CARPENTER, Danielle MITCHEM, Jonathan B PLAMBECK-SUESS, Stacey M WORLEY, Lori A GOETZ, Brian D |
| description | To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
Survival analysis was conducted to determine if the prevalence of preoperative blood monocytes correlates with survival in patients with pancreatic cancer following tumor resection. Inflammatory monocyte prevalence in the blood and bone marrow of patients with pancreatic cancer and controls was compared. The immunosuppressive properties of inflammatory monocytes and macrophages in the blood and tumors, respectively, of patients with pancreatic cancer were assessed. CCL2 expression by human pancreatic cancer tumors was compared with normal pancreas. A novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
Monocyte prevalence in the peripheral blood correlates inversely with survival, and low monocyte prevalence is an independent predictor of increased survival in patients with pancreatic cancer with resected tumors. Inflammatory monocytes are increased in the blood and decreased in the bone marrow of patients with pancreatic cancer compared with controls. An increased ratio of inflammatory monocytes in the blood versus the bone marrow is a novel predictor of decreased patient survival following tumor resection. Human pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors. Patients with tumors that exhibit high CCL2 expression/low CD8 T-cell infiltrate have significantly decreased survival. In mice, CCR2 blockade depletes inflammatory monocytes and macrophages from the primary tumor and premetastatic liver resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis.
Inflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease. |
| doi_str_mv | 10.1158/1078-0432.ccr-13-0525 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3700620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1381101325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c611t-4f79aa76800be7b8adc1ab644e44bb86888dfc7ef664fe112ecedb31450fcc4c3</originalsourceid><addsrcrecordid>eNpVUV1v1DAQjBCIlsJPAPkFiZe0Xn8khgekU4BS6RColGfL8a2vRond2rkTB3--jnpt6ZNHuzOz3p2qeg30GECqE6Ctqqng7NjaVAOvqWTySXUIUrY1Z418WvAd56B6kfNvSkEAFc-rA8YbyUGow-rfWXCDGUczxbQj32KIdjdhAb0f_F8z-RjIJ7QJTcZMfpQChon83KSt35qB-FBqYW5P3pKuQEwfyIKcxwGJi4lcmLTGyYc1mS6RdN2SnXTdOSOLPz6_rJ45M2R8tX-Pql9fPl90X-vl99OzbrGsbQMw1cK1741pG0Vpj22vzMqC6RshUIi-V41SauVsi65phEMAhhZXfVlPUmetsPyo-njre7XpR1zZskEyg75KfjRpp6Px-nEn-Eu9jlvNW0obRovBu71BitcbzJMefbY4DCZg3GQNXAFQ4EwWqryl2hRzTujuxwDVc3B6DkXPoehyiCLVc3BF9-b_P96r7pIqhLd7gsnWDC6VW_v8wGslE1QIfgMpKaN6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1381101325</pqid></control><display><type>article</type><title>Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>SANFORD, Dominic E ; BELT, Brian A ; WANG-GILLAM, Andrea ; EBERLEIN, Timothy J ; DENARDO, David G ; GOEDEGEBUURE, Simon Peter ; LINEHAN, David C ; PANNI, Roheena Z ; MAYER, Allese ; DESHPANDE, Anjali D ; CARPENTER, Danielle ; MITCHEM, Jonathan B ; PLAMBECK-SUESS, Stacey M ; WORLEY, Lori A ; GOETZ, Brian D</creator><creatorcontrib>SANFORD, Dominic E ; BELT, Brian A ; WANG-GILLAM, Andrea ; EBERLEIN, Timothy J ; DENARDO, David G ; GOEDEGEBUURE, Simon Peter ; LINEHAN, David C ; PANNI, Roheena Z ; MAYER, Allese ; DESHPANDE, Anjali D ; CARPENTER, Danielle ; MITCHEM, Jonathan B ; PLAMBECK-SUESS, Stacey M ; WORLEY, Lori A ; GOETZ, Brian D</creatorcontrib><description>To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
Survival analysis was conducted to determine if the prevalence of preoperative blood monocytes correlates with survival in patients with pancreatic cancer following tumor resection. Inflammatory monocyte prevalence in the blood and bone marrow of patients with pancreatic cancer and controls was compared. The immunosuppressive properties of inflammatory monocytes and macrophages in the blood and tumors, respectively, of patients with pancreatic cancer were assessed. CCL2 expression by human pancreatic cancer tumors was compared with normal pancreas. A novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
Monocyte prevalence in the peripheral blood correlates inversely with survival, and low monocyte prevalence is an independent predictor of increased survival in patients with pancreatic cancer with resected tumors. Inflammatory monocytes are increased in the blood and decreased in the bone marrow of patients with pancreatic cancer compared with controls. An increased ratio of inflammatory monocytes in the blood versus the bone marrow is a novel predictor of decreased patient survival following tumor resection. Human pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors. Patients with tumors that exhibit high CCL2 expression/low CD8 T-cell infiltrate have significantly decreased survival. In mice, CCR2 blockade depletes inflammatory monocytes and macrophages from the primary tumor and premetastatic liver resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis.
Inflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-13-0525</identifier><identifier>PMID: 23653148</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antineoplastic agents ; Biological and medical sciences ; Bone Marrow Cells - immunology ; Cell Movement - immunology ; Chemokine CCL2 - immunology ; Chemokine CCL2 - metabolism ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Knockout Techniques ; Humans ; Immunophenotyping ; Leukocyte Count ; Liver Neoplasms - secondary ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Mice ; Monocytes - immunology ; Monocytes - metabolism ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Pancreatic Neoplasms - immunology ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pharmacology. Drug treatments ; Phenotype ; Prognosis ; Receptors, CCR2 - genetics ; Receptors, CCR2 - metabolism ; Tumors</subject><ispartof>Clinical cancer research, 2013-07, Vol.19 (13), p.3404-3415</ispartof><rights>2014 INIST-CNRS</rights><rights>2013 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c611t-4f79aa76800be7b8adc1ab644e44bb86888dfc7ef664fe112ecedb31450fcc4c3</citedby><cites>FETCH-LOGICAL-c611t-4f79aa76800be7b8adc1ab644e44bb86888dfc7ef664fe112ecedb31450fcc4c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,3343,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27524044$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23653148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SANFORD, Dominic E</creatorcontrib><creatorcontrib>BELT, Brian A</creatorcontrib><creatorcontrib>WANG-GILLAM, Andrea</creatorcontrib><creatorcontrib>EBERLEIN, Timothy J</creatorcontrib><creatorcontrib>DENARDO, David G</creatorcontrib><creatorcontrib>GOEDEGEBUURE, Simon Peter</creatorcontrib><creatorcontrib>LINEHAN, David C</creatorcontrib><creatorcontrib>PANNI, Roheena Z</creatorcontrib><creatorcontrib>MAYER, Allese</creatorcontrib><creatorcontrib>DESHPANDE, Anjali D</creatorcontrib><creatorcontrib>CARPENTER, Danielle</creatorcontrib><creatorcontrib>MITCHEM, Jonathan B</creatorcontrib><creatorcontrib>PLAMBECK-SUESS, Stacey M</creatorcontrib><creatorcontrib>WORLEY, Lori A</creatorcontrib><creatorcontrib>GOETZ, Brian D</creatorcontrib><title>Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
Survival analysis was conducted to determine if the prevalence of preoperative blood monocytes correlates with survival in patients with pancreatic cancer following tumor resection. Inflammatory monocyte prevalence in the blood and bone marrow of patients with pancreatic cancer and controls was compared. The immunosuppressive properties of inflammatory monocytes and macrophages in the blood and tumors, respectively, of patients with pancreatic cancer were assessed. CCL2 expression by human pancreatic cancer tumors was compared with normal pancreas. A novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
Monocyte prevalence in the peripheral blood correlates inversely with survival, and low monocyte prevalence is an independent predictor of increased survival in patients with pancreatic cancer with resected tumors. Inflammatory monocytes are increased in the blood and decreased in the bone marrow of patients with pancreatic cancer compared with controls. An increased ratio of inflammatory monocytes in the blood versus the bone marrow is a novel predictor of decreased patient survival following tumor resection. Human pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors. Patients with tumors that exhibit high CCL2 expression/low CD8 T-cell infiltrate have significantly decreased survival. In mice, CCR2 blockade depletes inflammatory monocytes and macrophages from the primary tumor and premetastatic liver resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis.
Inflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Cells - immunology</subject><subject>Cell Movement - immunology</subject><subject>Chemokine CCL2 - immunology</subject><subject>Chemokine CCL2 - metabolism</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Knockout Techniques</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Leukocyte Count</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Monocytes - immunology</subject><subject>Monocytes - metabolism</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Pancreatic Neoplasms - immunology</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenotype</subject><subject>Prognosis</subject><subject>Receptors, CCR2 - genetics</subject><subject>Receptors, CCR2 - metabolism</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUV1v1DAQjBCIlsJPAPkFiZe0Xn8khgekU4BS6RColGfL8a2vRond2rkTB3--jnpt6ZNHuzOz3p2qeg30GECqE6Ctqqng7NjaVAOvqWTySXUIUrY1Z418WvAd56B6kfNvSkEAFc-rA8YbyUGow-rfWXCDGUczxbQj32KIdjdhAb0f_F8z-RjIJ7QJTcZMfpQChon83KSt35qB-FBqYW5P3pKuQEwfyIKcxwGJi4lcmLTGyYc1mS6RdN2SnXTdOSOLPz6_rJ45M2R8tX-Pql9fPl90X-vl99OzbrGsbQMw1cK1741pG0Vpj22vzMqC6RshUIi-V41SauVsi65phEMAhhZXfVlPUmetsPyo-njre7XpR1zZskEyg75KfjRpp6Px-nEn-Eu9jlvNW0obRovBu71BitcbzJMefbY4DCZg3GQNXAFQ4EwWqryl2hRzTujuxwDVc3B6DkXPoehyiCLVc3BF9-b_P96r7pIqhLd7gsnWDC6VW_v8wGslE1QIfgMpKaN6</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>SANFORD, Dominic E</creator><creator>BELT, Brian A</creator><creator>WANG-GILLAM, Andrea</creator><creator>EBERLEIN, Timothy J</creator><creator>DENARDO, David G</creator><creator>GOEDEGEBUURE, Simon Peter</creator><creator>LINEHAN, David C</creator><creator>PANNI, Roheena Z</creator><creator>MAYER, Allese</creator><creator>DESHPANDE, Anjali D</creator><creator>CARPENTER, Danielle</creator><creator>MITCHEM, Jonathan B</creator><creator>PLAMBECK-SUESS, Stacey M</creator><creator>WORLEY, Lori A</creator><creator>GOETZ, Brian D</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130701</creationdate><title>Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis</title><author>SANFORD, Dominic E ; BELT, Brian A ; WANG-GILLAM, Andrea ; EBERLEIN, Timothy J ; DENARDO, David G ; GOEDEGEBUURE, Simon Peter ; LINEHAN, David C ; PANNI, Roheena Z ; MAYER, Allese ; DESHPANDE, Anjali D ; CARPENTER, Danielle ; MITCHEM, Jonathan B ; PLAMBECK-SUESS, Stacey M ; WORLEY, Lori A ; GOETZ, Brian D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c611t-4f79aa76800be7b8adc1ab644e44bb86888dfc7ef664fe112ecedb31450fcc4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Cells - immunology</topic><topic>Cell Movement - immunology</topic><topic>Chemokine CCL2 - immunology</topic><topic>Chemokine CCL2 - metabolism</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Knockout Techniques</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Leukocyte Count</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Monocytes - immunology</topic><topic>Monocytes - metabolism</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Pancreatic Neoplasms - immunology</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenotype</topic><topic>Prognosis</topic><topic>Receptors, CCR2 - genetics</topic><topic>Receptors, CCR2 - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SANFORD, Dominic E</creatorcontrib><creatorcontrib>BELT, Brian A</creatorcontrib><creatorcontrib>WANG-GILLAM, Andrea</creatorcontrib><creatorcontrib>EBERLEIN, Timothy J</creatorcontrib><creatorcontrib>DENARDO, David G</creatorcontrib><creatorcontrib>GOEDEGEBUURE, Simon Peter</creatorcontrib><creatorcontrib>LINEHAN, David C</creatorcontrib><creatorcontrib>PANNI, Roheena Z</creatorcontrib><creatorcontrib>MAYER, Allese</creatorcontrib><creatorcontrib>DESHPANDE, Anjali D</creatorcontrib><creatorcontrib>CARPENTER, Danielle</creatorcontrib><creatorcontrib>MITCHEM, Jonathan B</creatorcontrib><creatorcontrib>PLAMBECK-SUESS, Stacey M</creatorcontrib><creatorcontrib>WORLEY, Lori A</creatorcontrib><creatorcontrib>GOETZ, Brian D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SANFORD, Dominic E</au><au>BELT, Brian A</au><au>WANG-GILLAM, Andrea</au><au>EBERLEIN, Timothy J</au><au>DENARDO, David G</au><au>GOEDEGEBUURE, Simon Peter</au><au>LINEHAN, David C</au><au>PANNI, Roheena Z</au><au>MAYER, Allese</au><au>DESHPANDE, Anjali D</au><au>CARPENTER, Danielle</au><au>MITCHEM, Jonathan B</au><au>PLAMBECK-SUESS, Stacey M</au><au>WORLEY, Lori A</au><au>GOETZ, Brian D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>19</volume><issue>13</issue><spage>3404</spage><epage>3415</epage><pages>3404-3415</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
Survival analysis was conducted to determine if the prevalence of preoperative blood monocytes correlates with survival in patients with pancreatic cancer following tumor resection. Inflammatory monocyte prevalence in the blood and bone marrow of patients with pancreatic cancer and controls was compared. The immunosuppressive properties of inflammatory monocytes and macrophages in the blood and tumors, respectively, of patients with pancreatic cancer were assessed. CCL2 expression by human pancreatic cancer tumors was compared with normal pancreas. A novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
Monocyte prevalence in the peripheral blood correlates inversely with survival, and low monocyte prevalence is an independent predictor of increased survival in patients with pancreatic cancer with resected tumors. Inflammatory monocytes are increased in the blood and decreased in the bone marrow of patients with pancreatic cancer compared with controls. An increased ratio of inflammatory monocytes in the blood versus the bone marrow is a novel predictor of decreased patient survival following tumor resection. Human pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors. Patients with tumors that exhibit high CCL2 expression/low CD8 T-cell infiltrate have significantly decreased survival. In mice, CCR2 blockade depletes inflammatory monocytes and macrophages from the primary tumor and premetastatic liver resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis.
Inflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>23653148</pmid><doi>10.1158/1078-0432.ccr-13-0525</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2013-07, Vol.19 (13), p.3404-3415 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3700620 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animals Antineoplastic agents Biological and medical sciences Bone Marrow Cells - immunology Cell Movement - immunology Chemokine CCL2 - immunology Chemokine CCL2 - metabolism Gastroenterology. Liver. Pancreas. Abdomen Gene Knockout Techniques Humans Immunophenotyping Leukocyte Count Liver Neoplasms - secondary Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Mice Monocytes - immunology Monocytes - metabolism Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pancreatic Neoplasms - immunology Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pharmacology. Drug treatments Phenotype Prognosis Receptors, CCR2 - genetics Receptors, CCR2 - metabolism Tumors |
| title | Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A28%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammatory%20Monocyte%20Mobilization%20Decreases%20Patient%20Survival%20in%20Pancreatic%20Cancer:%20A%20Role%20for%20Targeting%20the%20CCL2/CCR2%20Axis&rft.jtitle=Clinical%20cancer%20research&rft.au=SANFORD,%20Dominic%20E&rft.date=2013-07-01&rft.volume=19&rft.issue=13&rft.spage=3404&rft.epage=3415&rft.pages=3404-3415&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-13-0525&rft_dat=%3Cproquest_pubme%3E1381101325%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1381101325&rft_id=info:pmid/23653148&rfr_iscdi=true |